618 related articles for article (PubMed ID: 30508073)
21. The cost of warfarin treatment for stroke prevention in patients with non-valvular atrial fibrillation in Russia from a collective perspective.
Briere JB; Bowrin K; Wood R; Roberts J; Tatarsky B
J Med Econ; 2017 Jun; 20(6):599-605. PubMed ID: 28151036
[TBL] [Abstract][Full Text] [Related]
22. [Anticoagulation for patients with non-valvular atrial fibrillation].
Mizoguchi T; Yasaka M
Nihon Rinsho; 2016 Apr; 74(4):627-33. PubMed ID: 27333751
[TBL] [Abstract][Full Text] [Related]
23. Uptake of non-vitamin K antagonist oral anti coagulants in patients with atrial fibrillation - a prospective cohort study.
Zimny M; Blum S; Ammann P; Erne P; Moschovitis G; Di Valentino M; Shah D; Schläpfer J; Vogt C; Tabord A; Kühne M; Sticherling C; Osswald S; Conen D
Swiss Med Wkly; 2017; 147():w14410. PubMed ID: 28322423
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
Wang CL; Wu VC; Kuo CF; Chu PH; Tseng HJ; Wen MS; Chang SH
J Am Heart Assoc; 2018 Aug; 7(15):e009263. PubMed ID: 30371232
[TBL] [Abstract][Full Text] [Related]
25. Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
Hellfritzsch M; Husted SE; Grove EL; Rasmussen L; Poulsen BK; Johnsen SP; Hallas J; Pottegård A
Basic Clin Pharmacol Toxicol; 2017 Feb; 120(2):187-194. PubMed ID: 27580086
[TBL] [Abstract][Full Text] [Related]
26. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study.
García-Sempere A; Hurtado I; Bejarano-Quisoboni D; Rodríguez-Bernal C; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G
PLoS One; 2019; 14(2):e0211681. PubMed ID: 30753227
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
28. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
[TBL] [Abstract][Full Text] [Related]
29. Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
Simons LA; Ortiz M; Freedman B; Waterhouse BJ; Colquhoun D
Curr Med Res Opin; 2017 Jul; 33(7):1337-1341. PubMed ID: 28425296
[TBL] [Abstract][Full Text] [Related]
30. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
[TBL] [Abstract][Full Text] [Related]
31. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
[TBL] [Abstract][Full Text] [Related]
32. Why switch from warfarin to NOACs?
Verdecchia P; Angeli F; Aita A; Bartolini C; Reboldi G
Intern Emerg Med; 2016 Apr; 11(3):289-93. PubMed ID: 26972708
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
[TBL] [Abstract][Full Text] [Related]
34. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.
Martinez C; Katholing A; Wallenhorst C; Freedman SB
Thromb Haemost; 2016 Jan; 115(1):31-9. PubMed ID: 26246112
[TBL] [Abstract][Full Text] [Related]
35. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study.
Larsen TB; Rasmussen LH; Gorst-Rasmussen A; Skjøth F; Lane DA; Lip GY
Am J Med; 2014 Dec; 127(12):1172-8.e5. PubMed ID: 25193361
[TBL] [Abstract][Full Text] [Related]
36. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland.
Maeder MT; König T; Bogdanovic S; Schneider I; Eugster W; Ammann P; König M; Beer J; Rickli H
Swiss Med Wkly; 2017; 147():w14503. PubMed ID: 29039622
[TBL] [Abstract][Full Text] [Related]
37. Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends.
Shiyovich A; Shalev V; Chodick G; Tirosh M; Katz A; Klar MM; Shuvy M; Pereg D; Minha S
BMC Cardiovasc Disord; 2021 Oct; 21(1):493. PubMed ID: 34645389
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
39. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
40. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
